Reg­u­la­to­ry trou­bles around its peanut al­ler­gy treat­ment have hurt DBV Tech­nolo­gies bad.

It be­came even clear­er Thurs­day morn­ing as the French biotech dis­closed the scope of a glob­al re­struc­tur­ing it an­nounced back in June. More than 200 jobs are be­ing cut, leav­ing a team of 90 to car­ry on with the hard task of scor­ing ap­proval for its Vi­askin Peanut patch.

Daniel Tassé

With a for­mal go-ahead from au­thor­i­ties in France, CEO Daniel Tassé ex­pects the mea­sures to re­duce av­er­age month­ly cash burn by up to half, there­by keep­ing the com­pa­ny afloat un­til late 2022.

The trou­bles for DBV be­gan more than two years ago, when DBV pulled its first FDA sub­mis­sion. Back then, it had been in a neck-to-neck race with Aim­mune to de­liv­er the first prod­uct that can help chil­dren build up tol­er­ance to peanuts.

While Aim­mune — now ac­quired by Nes­tle — has a pill, DBV is en­gi­neer­ing a patch for kids to wear hours at a time. The FDA, how­ev­er, has tak­en is­sue with man­u­fac­tur­ing pro­ce­dures and qual­i­ty con­trols as well as patch ad­he­sion. Soon af­ter the com­pa­ny re­vealed the re­struc­tur­ing plans, its sec­ond ap­pli­ca­tion was re­ject­ed.

DBV has not stat­ed when it plans to re­file a BLA, but Tassé notes that the fu­ture fo­cus will be on “late stages of clin­i­cal de­vel­op­ment.” Oth­er than Vi­askin Peanut, the biotech al­so has patch pro­grams for cow’s milk al­ler­gy and hen’s egg al­ler­gy.

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech employees around the world, they occupy very few places in C-suites, and even fewer make it to the helm.

Some companies are listening, according to a recent BIO survey which showed that this year’s companies were 2.5 times more likely to have a diversity and inclusion program compared to last year’s sample. But we still have a long way to go. Women represent just 31% of biotech executives, BIO reported. And those numbers are even more stark for women of color.